… occurred in 114 patients (98%), with the median time to neutrophil recovery of 23 days for
recipients of related and 25 days for those that received unrelated allografts. High-dose …

… Beyond the multitude of choices regarding donor source, progress during the last 15
years has also shown that G-CSF-mobilized PBSC allografts provide a reliable source for …

… , alloantibodies may mediate a substantial proportion of organ allograft rejection episodes,
contributing to both early and late graft loss 33, 34. Antibody-mediated rejection may also …

… The transplant-related mortality in the early post-transplant period … have an impact on early
post-transplant immune recovery. … allografts compared to in recipients of BM allografts despite …

… A recent study of 25 second allografts, mainly for relapsed acute … of transplant, which
may progress in the early post-transplant period. Additionally, with the possibility of post-transplant …

… Thus, current approaches to haploidentical HCT rely on T-cell depletion from the allograft to
… HLA-haploidentical transplantation with post-transplant cyclophosphamide is an intriguing …

… allografts, and 47 received unrelated allografts. GVHD prophylaxis was solely with PTCy at
50 mg/kg/day on post-transplantation … allogeneic stem cell transplantation for the treatment of …

… from an allograft in CR1 should proceed to transplant as swiftly as possible. An important
factor influencing the decision to allograft in CR1 … MRD status and relapse risk post-allograft. …

Background Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative
option for multiple myeloma (MM). We analyzed our experience of allo-HCT in MM and …

… recovery (except in the recipients of a T-cell depleted allograft) and results in particular in …
of haploidentical transplants being performed with post-transplant cyclophosphamide being …